insights_auto
Miks on BT3 tõusnud? 8,66%?
Uurige põhjalikumaltchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
0,89 €
arrow_upward
+8,66%(+0,071) 1 p
9. okt, 22:00:00 GMT +2 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse BT3 põhistatistika genereerimine…
Ava
0,89 €
Kõrge
0,89 €
Madal
0,89 €
Turu kapit.
251,39Â mln
Keskm. maht
37,00
Maht
0,00
52 näd kõrgeim
1,69 €
52 näd madalaim
0,78 €
Töötajate arv
75
Ava
0,89 €
Kõrge
0,89 €
Madal
0,89 €
Turu kapit.
251,39Â mln
Keskm. maht
37,00
Maht
0,00
52 näd kõrgeim
1,69 €
52 näd madalaim
0,78 €
Töötajate arv
75
Uudised
Veebiallikatest ja uudistepartneritelt
The Globe and Mail
·
1 tunni eest
Streamex Receives Nasdaq Notice on Minimum Bid Price
Yahoo Finance
·
8 tunni eest
Prediction: This Is What a $5,000 Investment in the Vanguard S&P 500 ETF (VOO) Will Be Worth by 2040
Investor's Business Daily
·
6 tunni eest
Futures: 6 Stocks Near Buy Points; Big Earnings, Inflation Data Due
Seeking Alpha
·
8 tunni eest
The 1-Minute Market Report October 10, 2026 (NYSEARCA:VOO)
Profiil
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Teave üksuse Lineage Cell Therapeutics Inc kohta